Literature DB >> 23722322

Reduction of the washout time between natalizumab and fingolimod.

Jérôme de Seze, Jean-Claude Ongagna, Nicolas Collongues, Christophe Zaenker, Sylvie Courtois, Marie Fleury, Aurélien Benoilid, Jean-Baptiste Chanson, Frédéric Blanc.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23722322     DOI： 10.1177/1352458513490551

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  8 in total

1.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

2.  Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.

Authors:  Jonathan Zurawski; Ashley Flinn; Lindsay Sklover; Jacob A Sloane
Journal:  J Neurol       Date:  2016-05-18       Impact factor: 4.849

3.  Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Authors:  Per Soelberg Sorensen; Nils Koch-Henriksen; Thor Petersen; Mads Ravnborg; Annette Oturai; Finn Sellebjerg
Journal:  J Neurol       Date:  2014-04-12       Impact factor: 4.849

4.  Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Giancarlo Comi; Xavier Montalban; Helmut Butzkueven; Heinz Wiendl; Gavin Giovannoni; Hans-Peter Hartung; Tobias Derfuss; Yvonne Naegelin; Till Sprenger; Nicole Mueller-Lenke; Sarah Griffiths; Philipp von Rosenstiel; Rebecca Gottschalk; Ying Zhang; Frank Dahlke; Davorka Tomic
Journal:  Neurology       Date:  2015-05-29       Impact factor: 9.910

Review 5.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

6.  Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.

Authors:  Raed Alroughani; Samar Farouk Ahmed; Raed Behbehani; Jasem Al-Hashel
Journal:  Neurol Ther       Date:  2017-08-05

7.  Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Authors:  Cyra E Leurs; Zoé LE van Kempen; Iris Dekker; Lisanne J Balk; Mike P Wattjes; Theo Rispens; Bernard Mj Uitdehaag; Joep Killestein
Journal:  Mult Scler       Date:  2017-08-21       Impact factor: 6.312

Review 8.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.